The use of vancomycin with its therapeutic and adverse effects: A review

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 4, 2015, Pages 694-700

  Bruniera, F R ^a   Ferreira, F M ^a   Saviolli, L R M ^b   Bacci, M R ^a   Feder, D ^a   Pedreira, M Da Luz Gonçalves ^b   Peterlini, M A Sorgini ^b   Azzalis, L A ^b   Junqueira, V B Campos ^b   Fonseca, F L A ^a,b  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Endothelial injury; Oxidative stress; Toxicity; Vancomycin

Indexed keywords

FREE RADICAL; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ALLERGIC REACTION; ANTIBACTERIAL ACTIVITY; ARTICLE; CHILL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG THERAPY; DRUG USE; FEVER; HUMAN; HYPERSENSITIVITY; HYPOTENSION; INTERSTITIAL NEPHRITIS; NEPHROTOXICITY; NEUTROPENIA; PHLEBITIS; SIDE EFFECT; CHEMICALLY INDUCED; DRUG EFFECTS; GRAM POSITIVE BACTERIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; VANCOMYCIN;

EID: 84938063541     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. GUPTA A, BIYANI M, KHAIRA A. Vancomycin nephrotoxicity: myths and facts. Neth J Med 2011; 69: 379-383.
2. DEHORITY W. Use of vancomycin in pediatrics. Pediatr Infect Dis J 2010; 29: 462-464.
3. ANVISA. BRAZILIAN NATIONAL HEALTH AGENCY. http://www4.anvisa.gov.br/base/visadoc/BM/BM[2 6312-1-0] (20 October 2013, date last accessed).
4. CHAMBERS HF. Antimicrobial agents: Protein Synthesis Inhibitors and miscellaneous antibacterial agents. In: Goodman and Gilman's the pharmacological basis of therapeutics 11th edition. Edited by Joel G. Hardman, Lee E. Limbird. New York, McGraw-Hill, 2010; pp. 1074-1077.
5. HICKS RW, HERNANDEZ J. Perioperative pharmacology: a focus on vancomycin. AORN J 2011; 93: 593-599.
6. PLAN O, CAMBONIE G, BARBOTTE E, MEYER P, DEVINE C, MILESI C, PIDOUX O, BADR O, PICAUD JC. Continuousinfusion vancomycin therapy for preterm neonates with suspected or documented Grampositive i nfections: a new dosage schedule. Arch Dis Child Fetal Neonatal 2008; 93: 418-421.
7. BADRAN EF, SHAMAYLEH A, IRSHAID YM. Pharmacokinetics of vancomycin in neonates admitted to the neonatology unit a t the Jordan University Hospital. Int J Clin Pharmacol Ther 2011; 49: 252-257.
8. ROSZELL S, JONES C. Intravenous administration issues: A comparison of intravenous insertions and complications in vanco mycin versus other antibiotics. J Infusion Nurs 2010; 33: 112-118.
9. NUNN MO, CORALLO CE, AUBRON C, POOLE S, DOOLEY MJ, CHENG AC. Vancomycin dosing: assessment of time to therapeutic co ncentration and predictive accuracy of pharmacokinetic modeling software. Ann Pharmacother 2011; 45: 757-763.
10. PRITCHARD L, BAKER C, LEGGETT J, SEHDEV P, BROWN A, BAYLEY BK. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med 2010; 123: 1143-1149.
11. KHOTAEI GT, JAM S, SEYED AS, MOTAMED F, NEJAT F, TAGHI M, ASHTIANI H, IZADYAR M. Mon itoring of serum vancomycin concentrations in pediatric patients with normal renal function. Acta Med Iran 2010; 48: 91-94.
12. MARIANI-KURKDJIAN P, NEBBAD H, AUJARD Y, BINGEN E. Monitoring seru m vancomycin concentrations in the treatment of Staphylococcus infections in children. Arch Pediatr 2008; 15: 1625-1629.
13. AGUILAR MJ, LISART RF, SEGURA RT, ALMIÑANA MA. Diseño y validación de un esquema de dosificación de vancomicina en neonatos prematuros. Anales de Pediatría 2008; 68: 117-123.
14. ZEGBEH H, BLEYZAC N, BERHOUNE C, BERTRAND Y. Vancomycin: What dosages are needed to achieve efficacy in paediatric hematology/oncology? Archives de Pediatrie 2011; 18: 850-855.
15. OKTEM F, ARSLAN MK, OZGUNER F, CANDIR O, YILMAZ HR, CIRIS M, UZ E. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine. Toxicology 2005 ; 215: 227-233.
16. CETIN H, OLGAR S, OKTEM F, CIRIS M, UZ E, ASLAN C, OZGUNER F. Novel evidence suggesting an anti-oxidant property for erythropoietin on vancomycin-induced nephrotoxicity in a rat model. Clin Exp Pharmacol Physiol 2007; 34: 1181-1185.
17. DIETERICH C, PUEY A, LIN S, SWEZEY R, FURIMSKY A, FAIRCHILD D, MIRSALIS JC, NG HH. Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates. Toxicol Sci 2009; 107: 258-269.
18. JELASSI ML, BENLMOUDEN A, LEFEUVRE S, MAINARDI JL, BILLAUD EM. Level of evidence for therapeutic drug monitoring of vancomycin. Therapie 2011; 66: 29-37.
19. OUDIN C,VIALET R,BOULAMERY A,MARTIN C,SIMON N. Vancomycin prescription in neonate s and young infants: toward a simplified dosage Arch Dis Child Fetal Neonatal Ed 2011, 96, 365-370.
20. LOMAESTRO BM. Vancomycin dosing and monitoring 2 years after the guidelines. Exp Rev Anti-Infect Ther 2011; 9: 657-667.
21. KASIAKOU SK, SERMAIDES GJ, MICHALOPOULOS A, SOTERIADES ES, FALAGAS ME. Continuous versus intermittent intravenous administration of antibiotics: a meta-Analysis of ran domised controlled trials. Lancet Infect Dis 2005; 5: 581-589.
22. HADAWAY L, CHAMALLAS SN. Vancomycin: new perspectives on an old drug. J Infusion Nurs 2003; 26: 278-284.
23. SCHÄFER M, SCHNEIDER TR, SHELDRICK GM. Crystal structure of vancomycin. Curr Biol 1996; 4: 1509-1515.
24. HAZLEWOOD KA, BROUSE SD, PITCHER WD, HALL RG. Vancomycin-Associated nephrotoxicity: Grave concern or death by character assassination? Am J Med 2010; 123: 182-187.
25. EILAND LS, ENGLISH TM, EILAND EH. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother 2011; 45: 582-589.
26. MACHADO JKK, FEFERBAUM R, DINIZ EMA, OKAY TS, CECCON MEJ, VAZ FAC. Monitorização da terapěutica com vancomicina em recém-nascidos de termo com sepse, utilização e importəncia clínica. Rev Hosp Clin 2001; 56: 17-24.
27. GIACHETTO GA, TELECHEA HM, SPERANZA N, OYARZUN M, NANNI L, MENCHACA A. Vancomy cin pharmacokinetic-pharmacodynamic parameters to optimize dosage administration in critically ill children. Pediatr Crit Care Med 2010; 12: 250-254.
28. VASCONCELOS R, CRIADO PR, SANTI CG. Reações cutəneas medicamentosas. In: Martins HS, Neto RAB, Neto AS, Velasco IT, editors. Emergěncias clínicas: abordagem prá tica. 8 ed. Barueri: Manole, 2013; cap. 85, pp. 1138-1143.
29. TOXNET. [Internet]. Uni ted States National Library of Medicine. Disponível em: http://toxnet.nlm.nih.gov. (11 March 2013, date last accessed).
30. DAILY MED. [Internet]. United States National Library of Medicine. Disponível em: http://dailymed. nlm.nih.gov. (20 June 2012, date last accessed).
31. GUYTON AC, HALL JE. In: Resistěncia do corpo á infecção: Imunidade e alergia. Tratado de fisiologia médica. 11 ed. Rio de Janeiro: Elsevier, 2006; cap. 34, pp. 449-450.
32. SIN YC, ONISHKO C, TURNER S, COULTHARD K, MCKINNON R. Incidence of vancomycin-induced red man syndrome in a women's and children's hospital. J Pharmacy Pract Res 2007; 37: 124-126.
33. RICHTER J, ZHOU J, PAVLOVIC D, SCHEIBE R, BAC VH, BLUMENTHAL J, HUNG O, MURPHY MF, WHYNOT S, LEHMANN C. Vancomycin and to lesser extent tobramycin have vasomodulato ry effects in experimental endotoxemia in the rat. Clin Hemorheol Microcirc 2010; 46: 37-49.
34. CHOEN FJ. Os vasos sanguíneos. In: Robbins SL, Cotran RS, editors. Bases patológicas das doenças. Patologia. 7th ed. Rio de Janeiro: Elsevier, 2005; cap. 11, pp. 538-541.
35. COSTA VH, APARECIDO LB, JORGETTI V, COLOMBO FC, KREIEGER EM, GALVÃO LJJ. Estresse oxidativo e disfunção endotelial na doenç a renal crǒnica. Arq Bras Cardiol 2009; 92: 413-418.
36. ROBIBARO B, VORBACH H, WEIGEL G, WEIHS A, HLOUSEK M, PRESTERL E, GEORGOPOULOS A, GRIESMACHER A, GRANINGER W. In fluence of glycopeptide antibiotics on purine metabolism of endothelial cells. Adv Exp Med Biol 1998; 431: 833-838.
37. ELYASI S, KHALILI H, DASHTI-KHAVIDAKI S, MOHAMMADPOUR A, BERTRAND Y. Va ncomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 2012; 68: 1243-1255.
38. ROBIBARO B, VORBACH H, WEIGEL G, WEIHS A, HLOUSEK M, PRESTERL E, GEORGOPOULOS A, GRIESMACHER A, GRANINGER W. Endothelial cell compatibility of glycopeptide antibiotics for intravenous use. J Antimicrob Chemother 1998; 41: 297-300.
39. BASARSLAN F, YILMAZ N, ATES S, OZGUR T, TUTANC M, MOTOR VK, ARICA V, YILMAZ C, INCI M, BUYUKBAS S. Protective effects of thymoquinone on vancomycin-induced nephrotoxicity in rats. Hum Exp To xicol 2012; 31: 726-733.
40. DIETERICH C,PUEY A,LIN S,SWEZEY R,FURIMSKY A,FAIRCHILD D,MIRSALIS JC,NG HH Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates.Toxicol Sci 2009 107, 258-269.
41. SHAH-KHAN F, SCHEETZ MH, GHOSSEIN C. Biopsyproven acute tubular necrosis due to vancomycin toxicity. Int J Nephrol 2011; 2011: 4 pages.
42. WONG-BERINGER A, JOO J, TSE E, BERINGER P. Vacomycin-Associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011; 37: 95-101.